F10 and triple-A syndrome: In contrast, the simultaneous inhibition of FXa and FXa/FIIa can suppress AAA growth, reduce steroid receptor activator levels, reduce PAR-2 and MMP-2 expression, and reduce Smad 2/3 phosphorylation.